Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3473]

Osimertinib plus chemo improves survival across high-risk subgroups in EGFR...

Dr Pasi Janne - Dana-Farber Cancer Institute, Boston, USA

Osimertinib plus chemo improves survival across high-risk subgroups in EGFR-mutated aNSCLC ( Dr Pasi Janne - Dana-Farber Cancer Institute, Boston, USA )

Low-dose pembrolizumab plus neoadjuvant chemo option for TNBC in resource...

Dr Atul Batra - All India Institute Of Medical Sciences Delhi, New Delhi, India

Low-dose pembrolizumab plus neoadjuvant chemo option for TNBC in resource-constrained settings ( Dr Atul Batra - All India Institute Of Medical Sciences Delhi, New Delhi, India )

Domvanalimab, zimberelimab and FOLFOX shows durable survival in advanced HER2...

Dr Yelena Janjigian - Memorial Sloan Kettering Cancer Center, New York, USA

Domvanalimab, zimberelimab and FOLFOX shows durable survival in advanced HER2-negative GC/GEJC/EAC ( Dr Yelena Janjigian - Memorial Sloan Kettering Cancer Center, New York, USA )

Abemaciclib combined with endocrine therapy improves OS in high-risk HR+, HER2−...

Prof Stephen Johnston - The Royal Marsden, London, UK

Abemaciclib combined with endocrine therapy improves OS in high-risk HR+, HER2− early breast cancer ( Prof Stephen Johnston - The Royal Marsden, London, UK )

Avelumab maintenance after reduced chemotherapy cycles improves QoL without...

Dr Enrique Grande - MD Anderson Cancer Center Madrid, Madrid, Spain

Avelumab maintenance after reduced chemotherapy cycles improves QoL without sacrificing survival in aUC ( Dr Enrique Grande - MD Anderson Cancer Center Madrid, Madrid, Spain )

Apalutamide and salvage radiotherapy benefits luminal B subtype prostate cancer

Prof Daniel Spratt - University Hospitals Cleveland Medical Center, Cleveland...

Apalutamide and salvage radiotherapy benefits luminal B subtype prostate cancer ( Prof Daniel Spratt - University Hospitals Cleveland Medical Center, Cleveland, USA )

Bladder cancer updates from the first half of 2025

Dr Alison Birtle, Dr Ignacio Durán, Prof Evanguelos Xylinas, Dr Giuseppe Simone...

Bladder cancer updates from the first half of 2025 ( Dr Alison Birtle, Dr Ignacio Durán, Prof Evanguelos Xylinas, Dr Giuseppe Simone and Dr Benjamin Pradere )

Improving efficacy and toxicity reporting - and treatment insights from an...

Dr Ross Camidge - University of Colorado School of Medicine, Aurora, Colorado

Improving efficacy and toxicity reporting - and treatment insights from an oncologist patient ( Dr Ross Camidge - University of Colorado School of Medicine, Aurora, Colorado )

WCLC 2025: Latest in EGFR positive NSCLC

Prof Enriqueta Felip, Dr Antonio Passaro, Dr Alex Spira and Prof Ignacio Gil...

WCLC 2025: Latest in EGFR positive NSCLC ( Prof Enriqueta Felip, Dr Antonio Passaro, Dr Alex Spira and Prof Ignacio Gil-Bazo )

Dose escalation of RG6344 demonstrates safety and promising activity in BRAF...

Dr Maria Vieito - Vall d'Hebron Institute of Oncology, Barcelona, Spain

Dose escalation of RG6344 demonstrates safety and promising activity in BRAF V600E solid tumours ( Dr Maria Vieito - Vall d'Hebron Institute of Oncology, Barcelona, Spain )

Phase I/II trial shows promising activity of invikafusp alfa in PD-1–resistant...

Dr Elena Élez - Vall d'Hebron Institute of Oncology, Barcelona, Spain

Phase I/II trial shows promising activity of invikafusp alfa in PD-1–resistant GI cancers ( Dr Elena Élez - Vall d'Hebron Institute of Oncology, Barcelona, Spain )

Nivolumab plus ipilimumab improves survival results in MSI-H/dMMR metastatic...

Dr Elena Élez - Vall d'Hebron Institute of Oncology, Barcelona, Spain

Nivolumab plus ipilimumab improves survival results in MSI-H/dMMR metastatic colorectal cancer ( Dr Elena Élez - Vall d'Hebron Institute of Oncology, Barcelona, Spain )

More from ecancer